An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Atezolizumab; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms T-DM1 study
- Sponsors Chugai Pharmaceutical; Genentech; Roche
Most Recent Events
- 02 Jan 2025 Planned End Date changed from 20 Sep 2029 to 30 Sep 2029.
- 02 Jan 2025 Planned primary completion date changed from 20 Sep 2029 to 30 Sep 2029.
- 12 Jul 2024 Status changed from recruiting to active, no longer recruiting.